<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03001804</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-037</org_study_id>
    <nct_id>NCT03001804</nct_id>
  </id_info>
  <brief_title>Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients</brief_title>
  <official_title>Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this non-interventional study is to collect primarily the percentage of patients
      who receive the full dose of dexamethasone (40 mg orally once daily on days 1, 8, 15 and 22
      of the repetitive 28-day cycles, 20 mg in&gt; 75 year old patients) and in the registered
      indication under practice conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma is still a persistent and life-threatening blood cancer that is
      characterised by tumour proliferation and suppression of the immune system. It is a rare but
      incurable disease. On average, multiple myeloma is diagnosed in people 65-74 years of age,
      and the majority of newly diagnosed patients may not be eligible for more aggressive
      treatment options such as high-dose chemotherapy with stem cell transplant. In February 2015
      REVLIMID® (lenalidomide) was approved in combination with dexamethasone for the treatment of
      adult patients with previously untreated multiple myeloma who are not eligible for
      transplant. Looking in more detail at the combination of lenalidomide and dexamethasone, the
      role and especially the most adequate and effective dosage of dexamethasone in long term use
      with lenalidomide is not clearly defined or well characterised It is therefore of great
      relevance to gain insights into the clinical practice and the routine of dexamethasone
      management and dosing in long term use with Revlimid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients receiving full dose of dexamethasone after 6 months</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients that receive dexamethasone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Deep Venous Thrombosis (VTE) prophylaxis</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients that receive VTE prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over all response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients that achieve a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients with an adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide (Revlimid®) in combination with dexamethasone</arm_group_label>
    <description>Lenalidomide (Revlimid®) in combination with dexamethasone is indicated for the treatment of adult patients with untreated multiple myeloma, where stem cell transplantation cannot be performed.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for therapy of untreated multiple myeloma, where stem cell
        transplantation cannot be performed
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Age ≥ 18 years

          -  Newly diagnosed Multiple Myeloma

          -  Not suitable for stem cell transplantation

          -  Appropriate methods of contraception according to the Risk Minimization Program (RMP)

          -  Adequate thrombosis prophylaxis

        Exclusion Criteria:

          -  Pregnant and lactating females

          -  No other formal exclusion criteria according to most recent European Summary of
             Product Characteristics (SmPC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Voraberger</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KH der Elisabethinen Linz , 1. Interne Hämato-Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Ried Innere Medizin 1</name>
      <address>
        <city>Ried</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Steyr - Innere Medizin</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innere Medizin I, Abteilung Hämatologie &amp; Hämostaseologie</name>
      <address>
        <city>Vienna</city>
        <zip>1000 - 1901</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Josef Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salzkammergut-Klinikum Vöcklabruck Abteilung Innere Medizin</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Non-transplantable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

